A detailed history of Green Alpha Advisors, LLC transactions in Exact Sciences Corp stock. As of the latest transaction made, Green Alpha Advisors, LLC holds 4,469 shares of EXAS stock, worth $188,815. This represents 0.23% of its overall portfolio holdings.

Number of Shares
4,469
Previous 4,448 0.47%
Holding current value
$188,815
Previous $329,000 6.38%
% of portfolio
0.23%
Previous 0.24%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 09, 2024

BUY
$56.27 - $73.77 $1,181 - $1,549
21 Added 0.47%
4,469 $308,000
Q4 2023

Jan 04, 2024

SELL
$59.06 - $75.72 $26,281 - $33,695
-445 Reduced 9.09%
4,448 $329,000
Q3 2023

Oct 10, 2023

BUY
$65.94 - $99.04 $10,880 - $16,341
165 Added 3.49%
4,893 $333,000
Q2 2023

Jul 06, 2023

SELL
$62.68 - $95.05 $27,579 - $41,822
-440 Reduced 8.51%
4,728 $443,000
Q1 2023

Apr 06, 2023

SELL
$47.19 - $70.77 $9,626 - $14,437
-204 Reduced 3.8%
5,168 $350,000
Q4 2022

Jan 12, 2023

BUY
$30.35 - $53.15 $163,040 - $285,521
5,372 New
5,372 $0
Q2 2022

Jul 08, 2022

BUY
$35.61 - $76.23 $10,932 - $23,402
307 Added 6.05%
5,383 $212,000
Q1 2022

Apr 19, 2022

BUY
$57.56 - $82.54 $27,686 - $39,701
481 Added 10.47%
5,076 $355,000
Q4 2021

Jan 12, 2022

SELL
$72.5 - $100.68 $33,567 - $46,614
-463 Reduced 9.15%
4,595 $358,000
Q3 2021

Oct 12, 2021

BUY
$90.24 - $124.05 $63,348 - $87,083
702 Added 16.12%
5,058 $483,000
Q2 2021

Jul 22, 2021

BUY
$93.66 - $139.27 $155,381 - $231,048
1,659 Added 61.51%
4,356 $541,000
Q1 2021

Jul 22, 2021

BUY
$116.57 - $155.01 $314,389 - $418,061
2,697 New
2,697 $355,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $7.48B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Green Alpha Advisors, LLC Portfolio

Follow Green Alpha Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Green Alpha Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Green Alpha Advisors, LLC with notifications on news.